Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

Journal Articles

The Diagnostic Value of Kappa/Lambda Ratios Determined By Flow Cytometric Analysis of Peripheral Blood and Bone Marrow Specimens in B-Cell Chronic Proliferative Disease

Aldair Sousa Paiva, PhD, Alessandra Suelen Jardim, Victor lima Soares, Hugo Diogenes De Oliveira Paiva, MD, Frank Bahia, MD, Valéria SF Sales, PhD, Marcos Dias Leão, PhD, Antonia Eduarda Martins Oliveira Elói Silva, João Pedro Andrade Lima, Geraldo Barroso Cavalcanti, Jr., PhD

Blood (2018) 132 (Supplement 1): 5431.

https://doi.org/10.1182/blood-2018-99-119868

Published: 2018

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

Journal Articles

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

Carlos I. Amaya-Chanaga, MD, Michael Y. Choi, MD, Natalie Nguyen, B.Sc, Elizabeth DeVore, B.Sc, Colin MacCarthy, B.Sc, Jacqueline Hilger-Rolfe, PhD, M.S., Thomas J. Kipps, MD, PhD, Januario E. Castro, MD

Blood (2016) 128 (22): 2048.

https://doi.org/10.1182/blood.V128.22.2048.2048

Published: 2016

Journal Articles

A Population-Based Study of Large Granular Lymphocyte Leukemia: Analysis of 978 Patients Using the SEER and NCDB Databases

Mithun Vinod Shah, MD PhD, C Christopher Hook, MD, Timothy G. Call, MD, Ronald S. Go, MD

Blood (2015) 126 (23): 3302.

https://doi.org/10.1182/blood.V126.23.3302.3302

Published: 2015

Journal Articles

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Lotta Hansson, MD PhD, Maria Winqvist, MD, Anna Asklid, MD, P-O Andersson, MDPhD, Karin Karlsson, MD, Claes Karlsson, MDPhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD, Mattias Mattsson, MD, Stefan Norin, MDPhD, Anna Sandstedt, MD, Anders Österborg, MDPhD

Blood (2015) 126 (23): 1745.

https://doi.org/10.1182/blood.V126.23.1745.1745

Published: 2015

Journal Articles

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Jeff Sharman, Michael Hawkins, Kathryn Kolibaba, Michael Boxer, Leonard Klein, Meihua Wu, Jing Hu, Steve Abella, Chris Yasenchak

Blood (2015) 125 (15): 2336–2343.

https://doi.org/10.1182/blood-2014-08-595934

Published: 2015

Includes: Supplemental data

Journal Articles

Anergy in CLL: Moving Towards the Clinic

Benedetta Apollonio, Tania Veliz Rodriguez, Cristina Scielzo, PhD, Maria Teresa Sabrina Bertilaccio, Lydia Scarfò, Federico Caligaris-Cappio, MD, Paolo Ghia, MD PhD

Blood (2014) 124 (21): 4677.

https://doi.org/10.1182/blood.V124.21.4677.4677

Published: 2014

Journal Articles

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

Daphne Guinn, Amy S. Ruppert, MAS, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Amber L. Gordon, Thomas S. Lin, MD PhD, Richard A. Larson, Guido Marcucci, MD, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 3297.

https://doi.org/10.1182/blood.V124.21.3297.3297

Published: 2014

Journal Articles

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Howard A. Burris, MD, Manish R. Patel, MD, Danielle M. Brander, MD, Owen A. O'Connor, MD PhD, Changchun Deng, MD PhD, Timothy S. Fenske, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John Kuhn, PharmD, Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Ian Flinn

Blood (2014) 124 (21): 1984.

https://doi.org/10.1182/blood.V124.21.1984.1984

Published: 2014

Journal Articles

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Blood (2014) 123 (12): 1810–1817.

https://doi.org/10.1182/blood-2013-09-527853

Published: 2014

Includes: Supplemental data

Journal Articles

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

Mathilde Lamarque, MD, Véronique Leblond, MD, PhD, Bruno R. Varet, MD, Sylvain Choquet, MD, Jean Paul Vernant, MD, Richard Delarue, MD, Bertrand Godeau, MD, Olivier Hermine, MD, PhD, Marc Michel, IV

Blood (2013) 122 (21): 2193.

https://doi.org/10.1182/blood.V122.21.2193.2193

Published: 2013

Journal Articles

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Alessandra Ferrajoli, M.D., Stefan Faderl, MD, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, PhD, Danelle F. James, M.D., Joseph J. Buggy, PhD, Hagop M Kantarjian, Susan M. O'Brien

Blood (2012) 120 (21): 187.

https://doi.org/10.1182/blood.V120.21.187.187

Published: 2012

Journal Articles

Large Granular Lymphocyte Expansion Following Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with the Presence of CMV Reactivation and Probably with Acute GvHD and Shows An Indolent Outcome.

Sabine Nann, MD, Alexander Tzankov, MD, Nathan Cantoni, MD, Jörg Halter, MD, Dominik Heim, MD, Dimitrios Tsakiris, MD, Caroline Arber, MD, Andreas Buser, MD, Alois Gratwohl, MD, Andre Tichelli, MD, Alicia Rovo, MD

Blood (2010) 116 (21): 3461.

https://doi.org/10.1182/blood.V116.21.3461.3461

Published: 2010

Journal Articles

T-Cell Large Granular Lymphocyte (T-LGL) Expansion Post Adult Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) – ‘A Prognostic Indicator for Improved Overall Survival’.

Mayur S Ramesh, MD, Zaid Al-Kadhimi, MD, Stephanie Mellon-Reppens, NP, Jason Valent, MD, Lawrence G Lum, MD, DSc, Lois Ayash, MD, Muneer H Abidi, MD, Voravit Ratanatharathorn, MD, Joseph Uberti, MD, PhD

Blood (2009) 114 (22): 2241.

https://doi.org/10.1182/blood.V114.22.2241.2241

Published: 2009

Journal Articles

Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.

Dong Chen, MD, PhD, David S. Viswanatha, MD, Clive S. Zent, MD, Tait D. Shanafelt, M.D., Timothy G. Call, MD, Neil E. Kay, MD, Daniel L. Van Dyke, PhD, Rhett P. Ketterling, MD, Thomas E. Witzig, MD, William G. Morice, MD, PhD, Curtis A. Hanson, MD

Blood (2009) 114 (22): 3937.

https://doi.org/10.1182/blood.V114.22.3937.3937

Published: 2009

Journal Articles

Gene Expression Profiling of Persistent Polyclonal B-Cell Lymphocytosis Using Whole Genome Microarrays.

Charles H. Lawrie, DPhil, Xavier Troussard, Hossein Mossafa, Chris Hatton

Blood (2006) 108 (11): 4289.

https://doi.org/10.1182/blood.V108.11.4289.4289

Published: 2006

Journal Articles

Polyclonal B-Cell Lymphocytosis With Features Resembling Hairy Cell Leukemia-Japanese Variant

Takashi Machii, Mitsuhiro Yamaguchi, Ryoichi Inoue, Yukihiro Tokumine, Hirohiko Kuratsune, Hiroshi Nagai, Shunichi Fukuda, Kazumichi Furuyama, Osamu Yamada, Yoshito Yahata, Teruo Kitani

Blood (1997) 89 (6): 2008–2014.

https://doi.org/10.1182/blood.V89.6.2008

Published: 1997

Journal Articles

Glucocorticoid effects on peripheral blood lymphocytes in cows infected with bovine leukemia virus

JC Bloom, SJ Kenyon, TG Gabuzda

Blood (1979) 53 (5): 899–912.

https://doi.org/10.1182/blood.V53.5.899.899

Published: 1979

NARROW

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

The Diagnostic Value of Kappa/Lambda Ratios Determined By Flow Cytometric Analysis of Peripheral Blood and Bone Marrow Specimens in B-Cell Chronic Proliferative Disease

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with Coexisting Conditions

A Population-Based Study of Large Granular Lymphocyte Leukemia: Analysis of 978 Patients Using the SEER and NCDB Databases

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Anergy in CLL: Moving Towards the Clinic

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients

The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

Large Granular Lymphocyte Expansion Following Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with the Presence of CMV Reactivation and Probably with Acute GvHD and Shows An Indolent Outcome.

T-Cell Large Granular Lymphocyte (T-LGL) Expansion Post Adult Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) – ‘A Prognostic Indicator for Improved Overall Survival’.

Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.

Gene Expression Profiling of Persistent Polyclonal B-Cell Lymphocytosis Using Whole Genome Microarrays.

Polyclonal B-Cell Lymphocytosis With Features Resembling Hairy Cell Leukemia-Japanese Variant

Glucocorticoid effects on peripheral blood lymphocytes in cows infected with bovine leukemia virus

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only